BIO applauds unanimous Senate passage of the Adding Ebola to the FDA Priority Review Voucher Program Act. Bill would add Ebola to FDA's priority review voucher program, under which developers of vaccine or treatment for a qualifying tropical disease receive voucher for FDA priority review for another product of choice, or sold to another developer. If passed into law, act would provide companies with extremely valuable regulatory incentive to develop Ebola vaccines and treatments.